Benzinga | Aug 4, 2020 08:35AM EDT

Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $146

Morgan Stanley maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and lowers the price target from $149 to $146.